• 1. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 2. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 3. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300

(1H-1,3-benzodiazol-5-yl)methyl(methyl)amine (CAS No. 886851-32-7): An Overview of a Promising Compound in Medicinal Chemistry

(1H-1,3-benzodiazol-5-yl)methyl(methyl)amine (CAS No. 886851-32-7) is a versatile compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural features and potential therapeutic applications. This compound, often referred to as Benzodiazolylmethylamine, belongs to the class of benzodiazepines, which are widely known for their diverse biological activities, including anxiolytic, sedative, and anticonvulsant properties.

The chemical structure of (1H-1,3-benzodiazol-5-yl)methyl(methyl)amine consists of a benzodiazepine ring system linked to a methylamine group through a methyl bridge. This specific arrangement confers the compound with unique pharmacological properties that differentiate it from other members of the benzodiazepine family. Recent studies have highlighted its potential in various therapeutic areas, making it a subject of intense research and development.

One of the key areas of interest for (1H-1,3-benzodiazol-5-yl)methyl(methyl)amine is its role in the treatment of neurological disorders. Research has shown that this compound can modulate the activity of GABA receptors, which are central to the regulation of neuronal excitability. By enhancing GABAergic transmission, (1H-1,3-benzodiazol-5-yl)methyl(methyl)amine may offer new avenues for treating conditions such as anxiety disorders, epilepsy, and sleep disorders.

In addition to its neurological applications, (1H-1,3-benzodiazol-5-yl)methyl(methyl)amine has also been explored for its potential in cancer research. Preliminary studies have indicated that this compound can exhibit anti-proliferative effects on certain types of cancer cells. The mechanism behind this activity is not yet fully understood but is believed to involve the modulation of cell signaling pathways and apoptosis induction. These findings suggest that (1H-1,3-benzodiazol-5-yl)methyl(methyl)amine could be a valuable lead compound for the development of novel anticancer agents.

The synthesis and characterization of (1H-1,3-benzodiazol-5-yl)methyl(methyl)amine have been well-documented in the literature. Various synthetic routes have been developed to produce this compound with high purity and yield. One common approach involves the reaction of 5-(bromomethyl)-1H-benzodiazole with methylamine in the presence of a suitable base. The resulting product is then purified using standard techniques such as column chromatography or recrystallization.

The physicochemical properties of (1H-1,3-benzodiazol-5-yl)methyl(methyl)amine have also been extensively studied. It is a colorless solid with a molecular weight of approximately 207 g/mol. The compound exhibits good solubility in organic solvents such as methanol and dimethyl sulfoxide (DMSO), making it suitable for various experimental applications. Its melting point and other physical characteristics have been determined through rigorous analytical methods.

In terms of safety and toxicity, preliminary assessments suggest that (1H-1,3-benzodiazol-5-yl)methyl(methyl)amine has a favorable safety profile at therapeutic doses. However, as with any new chemical entity (NCE), comprehensive safety evaluations are essential before it can be considered for clinical use. Ongoing preclinical studies are focused on elucidating its pharmacokinetic properties and potential side effects.

The future prospects for (1H-1,3-benzodiazol-5-yl)methyl(methyl)amine are promising. Its unique combination of structural features and biological activities positions it as a potential candidate for further drug development. Collaborative efforts between academic researchers and pharmaceutical companies are underway to optimize its properties and explore its therapeutic potential in various disease models.

In conclusion, (1H-1,3-benzodiazol-5-yl)methyl(methyl)amine (CAS No. 886851-32-7) is an intriguing compound with significant potential in medicinal chemistry. Its ability to modulate GABA receptors and exhibit anti-proliferative effects makes it a valuable target for further research and development. As more studies are conducted, it is likely that new applications and insights will emerge, contributing to the advancement of drug discovery and therapeutic innovation.

• 164648-60-6(1H-1,3-benzodiazol-6-ylmethanamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)